Addex Therapeutics (ADXN) Income towards Parent Company (2022 - 2025)
Historic Income towards Parent Company for Addex Therapeutics (ADXN) over the last 4 years, with Q2 2025 value amounting to $142225.5.
- Addex Therapeutics' Income towards Parent Company fell 9910.28% to $142225.5 in Q2 2025 from the same period last year, while for Sep 2025 it was -$1.5 million, marking a year-over-year decrease of 11362.94%. This contributed to the annual value of $2.6 million for FY2024, which is 12538.75% up from last year.
- Latest data reveals that Addex Therapeutics reported Income towards Parent Company of $142225.5 as of Q2 2025, which was down 9910.28% from -$1.6 million recorded in Q1 2025.
- In the past 5 years, Addex Therapeutics' Income towards Parent Company ranged from a high of $15.9 million in Q2 2024 and a low of -$11.1 million during Q4 2024
- Its 4-year average for Income towards Parent Company is -$2.4 million, with a median of -$2.3 million in 2023.
- Its Income towards Parent Company has fluctuated over the past 5 years, first tumbled by 79604.48% in 2023, then skyrocketed by 76178.03% in 2024.
- Quarter analysis of 4 years shows Addex Therapeutics' Income towards Parent Company stood at $1.5 million in 2022, then tumbled by 796.04% to -$10.4 million in 2023, then dropped by 6.67% to -$11.1 million in 2024, then skyrocketed by 101.29% to $142225.5 in 2025.
- Its last three reported values are $142225.5 in Q2 2025, -$1.6 million for Q1 2025, and -$11.1 million during Q4 2024.